Tonix Pharmaceuticals Holding Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Tonix Pharmaceuticals Holding Corp. (TNXP) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-130.04-116.66-110.22-89.29-50.46-28.62-26.09
Depreciation & Amortization3.424.291.250.050.030.030.05
Stock Based Compensation4.789.2810.917.902.880.000.00
Change in Working Capital5.78-0.040.005.78-2.370.450.44
Change in Accounts Receivable-3.680.000.000.000.000.000.00
Change in Inventory3.740.060.000.000.000.000.00
Change in Accounts Payable0.93-3.49-1.053.531.530.000.00
Change in Other Working Capital4.793.391.043.00-3.890.000.00
Other Operating Activities-4.661.1910.917.902.881.460.00
Net Cash from Operating Activities-60.93-102.00-98.05-75.56-48.57-26.68-23.97
Investing Activities
Capital Expenditures-0.12-7.9048.1535.31-8.560.02-0.01
Acquisitions0.00-22.170.000.000.000.000.00
Net Cash from Investing Activities-0.12-29.07-48.15-35.31-8.56-0.02-0.01
Financing Activities
Debt Repayment-2.350.000.000.000.000.000.00
Common Stock Issued147.4621.7794.46212.39123.155.8423.54
Common Stock Repurchased0.00-13.97-47.250.000.000.000.00
Other Financing Activities-10.2419.77-9.74-10.51-5.360.000.00
Net Cash from Financing Activities134.8736.5287.84212.49123.1112.9223.54
Summary
Effect of Forex Changes on Cash0.00-0.07-0.07-0.03-0.020.00-0.01
Net Change in Cash73.83-94.62-58.36101.5965.96-13.78-0.44
Cash at Beginning of Period25.85120.47178.9077.3111.3525.1325.59
Cash at End of Period99.6825.85120.47178.9077.3111.3525.13
Free Cash Flow-61.05-109.90-146.20-110.86-57.13-26.70-23.98
Supplemental Disclosures
Interest Paid1.230.090.000.000.000.000.00
Income Taxes Paid0.000.000.000.000.000.000.08